The estrogen receptor beta (ERbeta) is emerging as an important regulator of pancreatic beta cell function (Soriano et al, 2009). Here we have evaluated the role of the ERbeta selective agonist, WAY200070, as an insulinotropic molecule and its antidiabetic actions in CB57 mice. We have demonstrated that it enhances glucose-stimulated insulin secretion (GSIS) both in mouse and human islets of Langerhans. In vivo experiments showed that a single-administration of WAY 200070 leads to an increase in plasma insulin levels with a concomitant improved response to a glucose load. Two-week treatment increased GSIS, pancreatic beta-cell mass and improved glucose and insulin sensitivity. In addition, streptozotocin-nicotinamide-induced diabetic mice treated with WAY200070 exhibited a significant improvement in plasma insulin levels and glucose tolerance as well as a regeneration of pancreatic beta-cell mass. Studies performed in db/db mice demonstrated that this compound restored first-phase insulin secretion, enhanced pancreatic beta-cell mass and favored the control of body weight. We conclude that ERbeta agonists should be considered as new targets for the treatment of diabetes (Alonso-Magdalena et al, 2013).
37th Congress of IUPS (Birmingham, UK) (2013) Proc 37th IUPS, SA391
Research Symposium: Oestrogen receptor beta: a new target for type 2 diabetes treatment
P. Alonso-Magdalena1, A. B. Ropero1, M. García-Arévalo1, S. Soriano1, I. Quesada1, S. J. Muhammed3, A. Salehi3, J. Gustafsson2, A. Nadal1
1. Universidad Miguel Hernandez de Elche, Elche (Alicante), Spain. 2. University of Houston, Houston, Texas, United States. 3. University of Lund, Malm÷, Sweden.
View other abstracts by:
Where applicable, experiments conform with Society ethical requirements.